- 2022, Volume 80 - Number 1
- Published: May 16, 2022
Dupilumab for recalcitrant prurigo nodularis: Case report
Joel Reis 1, Inês Raposo 2, Manuela Selores 3
1 Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal; 2 Department of Dermatology, University of Porto. Portugal; 3 Department of Dermatology; Department of Dermatology and Dermatology Research Unit, Centro Hospitalar Universitário do Porto; Instituto de Ciências Biomédicas Abel Salazar; Unit for Multidisciplinary Research in Biomedicine, University of Porto. Porto, Portugal
Joel Reis, Inês Raposo, Manuela Selores
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Inês Raposo, Email not available
Abstract
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. We present a case of recalcitrant prurigo nodularis treated off-label with dupilumab.
